3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Dermatologic
1
Conditions
Uveal Melanoma
1
Solid Tumor
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Glioma
1
Disease Progression
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
tebentafusp
4
Nivolumab
4
Magnetic Resonance Spectroscopy
3
Cyclophosphamide
3
pembrolizumab
2
fludarabine phosphate
2
fludarabine
2
cemiplimab
2
Specimen Handling
2
Ipilimumab
2
Interleukin-2
2
sargramostim
1
quisinostat
1
olaparib
1
lifileucel
1
binimetinib
1
aldesleukin
1
aflibercept
1
Valproic Acid
1
Spinal Puncture
1
Protein Kinase C
1
Melatonin
1
Interleukin-13
1
Hematologic Tests
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Fluorodeoxyglucose F18
1
Exercise
1
Crizotinib
1
Carmustine
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Uveal Melanoma
×
Valproic Acid
×
Clear all
NCT04729543
2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2
Recruiting
20 enrolled